AA
IONS icon

AlphaCentric Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

AlphaCentric Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Sell
15,430
-4,157
-21% -$313K 1.04% 19
2026
Q1 		$1.47M Buy
19,587
+1,064
+6% +$84K 1.47% 8
2025
Q4 		$1.47M Buy
+18,523
New +$1.39M 1.46% 10
2024
Q4 		$266K Buy
+7,614
New +$285K 0.27% 98

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

AlphaCentric Advisors's IONS Position: Q2 2026 in Review

AlphaCentric Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 21% in Q2 2026, selling an estimated $313K and leaving 15,430 shares worth $1.22M. The position accounts for 1.04% of the portfolio, ranked #19.

AlphaCentric Advisors first reported a position in IONS in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.47M in Q1 2026. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • AlphaCentric Advisors held 15,430 shares of Ionis Pharmaceuticals worth $1.22M as of Q2 2026.
  • AlphaCentric Advisors sold 4,157 Ionis Pharmaceuticals shares in Q2 2026, an estimated $313K.
  • Ionis Pharmaceuticals made up 1.04% of AlphaCentric Advisors's portfolio in Q2 2026, its #19 holding.
  • AlphaCentric Advisors first reported a position in Ionis Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • AlphaCentric Advisors's Ionis Pharmaceuticals position peaked at $1.47M in Q1 2026.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.